Clinical trial · Observational
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
NCT04777175CI-TRIAL-00080831recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunity therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- KRAS mutation
- description
- patients carry with KRAS mutation
- interventionNames
- Drug: immunity therapy
- label
- ALK fusion
- description
- patients carry with ALK fusion
- interventionNames
- Drug: immunity therapy
- label
- ERBB2 mutation
- description
- patients carry with ERBB2 mutation
- interventionNames
- Drug: immunity therapy
- label
- MET skipping/amplication
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: * The patient is diagnosed with small cell lung cancer
References
Publications (0)
Data not yet available
No reference posted for this study.